Diamyd, an alum-formulated recombinant human GAD65 for the prevention of autoimmune diabetes.
Diamyd Medical AB is developing Diamyd (GAD-65), an alum formulation of a full-length recombinant human glutamic acid decarboxylase 65 for subcutaneous injection, for the potential prevention and treatment of type 1 diabetes (T1DM) or latent autoimmune diabetes (LADA) in adults. Phase II clinical trials indicated that Diamyd was safe and well tolerated in patients with T1DM or LADA. Diamyd is currently in phase II/III and III clinical trials for T1DM.
Hinke
Simon A
SA
University of Washington, Department of Pharmacology, Seattle, WA 98195, USA. shinke@u.washington.edu
D000276:Adjuvants, Immunologic / Q000008:administration & dosage*; D000328:Adult; D000534:Alum Compounds / Q000008:administration & dosage*; D017322:Clinical Trials, Phase II as Topic; D017326:Clinical Trials, Phase III as Topic; D003922:Diabetes Mellitus, Type 1 / Q000517:prevention & control*; D005968:Glutamate Decarboxylase / Q000008:administration & dosage*; D006801:Humans; D007279:Injections, Subcutaneous; D011994:Recombinant Proteins / Q000008:administration & dosage*
D000276:Adjuvants, Immunologic; D000534:Alum Compounds; D011994:Recombinant Proteins; C041524:aluminum sulfate; D005968:Glutamate Decarboxylase; C401141:glutamate decarboxylase 2